Moderna puts up $120M to start cancer drug R&D alliance with Immatics

The latest stories trending on MedCity News.

Editor's Pick

Top Story Moderna Puts Up $120M to Start Cancer Drug R&D Alliance With Immatics Moderna and Immatics aim to see if the combination of their respective technologies can lead to better cancer treatments spanning multiple therapeutic modalities. Milestone payments to immunotherapy developer Immatics could top $1.7 billion. Sponsored Content Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women's Health Presented by AVIA Health and Seamless MD This webinar sponsored by AVIA Health and SeamlessMD will discuss the latest trends in remote monitoring and how to extend these benefits beyond chronic conditions all while using fewer staff resources. Other topics covered: Identify patient populations to scale remote monitoring beyond chronic care Know what good looks like when evaluating solutions Build the business case and secure clinical staff buy-in Orchestrate system-wide integration and implementation to streamline clinical workflows and efficiencies Register today to join the conversation. Designing Clinical Trials with Patients in Mind How are life science companies reimagining clinical trials? Find out on October 26th at Pegasus Park in Dallas and hear from these experts: Jodi Akin, Founder, Chairman + CEO, Hawthorne Effect and Kwame Marfo, Market Strategy and Innovation, Komodo Health. Moderated by Raj Rajendran, Associate Partner, McKinsey & Company. Reserve Your Seat

Featured News

FDA Approves Updated Covid-19 Vaccines to Address Now Circulating Variants The FDA said the updated messenger RNA vaccines from Pfizer/BioNTech and Moderna will protect against the omicron subvariants now prevalent in circulation. Left out of the FDA decision is Novavax, whose protein-based vaccine is still under regulatory review. Health Wildcatters Takes The Wraps Off Its Latest Cohort of Healthcare Startups The group of 10 startups in the accelerator have ambitions to improve early detection of lung cancer, eliminate contaminated needles, improve remote monitoring and provide new ways to treat head lice, among other goals. Pumpspotting Secures $2.2M To Expand Access to Breastfeeding Support Pumpspotting's funding round was led by Sincere Corporation and Maine Venture Fund and included participation from Unum Business Ventures and Maine Technology Institute. In total, pumpspotting has raised more than $3.3 million.

Resources

MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Andrew Trister, Chief Scientific Officer at Verily In this episode of MedCity Moves Podcast we were joined by Andrew Trister, who just became Verily's chief scientific officer. In this role, he will lead the company's population health initiatives and help advance its precision health strategies. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe